Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alkermes plc - Ordinary Shares (NQ:ALKS)

30.17 -0.29 (-0.95%)
Streaming Delayed Price Updated: 11:07 AM EDT, Jul 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alkermes plc - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Biogen Shares Slip After $46M Research Charge Hits Quarterly Profit
The company anticipates a research expense in Q2 associated with milestone and licensing payments, which will impact both GAAP and non-GAAP earnings per share. 
Via Stocktwits
ALKERMES PLC (NASDAQ:ALKS) – A Potential Undervalued Opportunity in Biopharma
ALKERMES PLC (NASDAQ:ALKS) shows strong profitability and financial health while trading at a discount to peers, making it a potential value opportunity in biopharma. 
Via Chartmill
Nvidia To Rally More Than 38%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
This Cooper Companies Analyst Turns Bullish; Here Are Top 3 Upgrades For Tuesday
Via Benzinga
Alkermes Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)
Via Benzinga
Earnings Scheduled For May 1, 2025
Via Benzinga
NASDAQ:ALKS: good value for what you're paying.
Uncover the potential of ALKERMES PLC, an undervalued stock. NASDAQ:ALKS maintains a strong financial position and offers an appealing valuation. 
Via Chartmill
Earnings Scheduled For February 12, 2025
Via Benzinga
Despite its impressive fundamentals, NASDAQ:ALKS remains undervalued.
ALKERMES PLC (NASDAQ:ALKS) appears to be flying under the radar despite its strong fundamentals. 
Via Chartmill
Alkermes Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)
Via Benzinga
This Arista Networks Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Via Benzinga
Beyond The Numbers: 6 Analysts Discuss Alkermes Stock
Via Benzinga
In a market where value is scarce, ALKERMES PLC (NASDAQ:ALKS) offers a refreshing opportunity with its solid fundamentals.
ALKERMES PLC is a hidden gem, featuring undervaluation and robust fundamentals. NASDAQ:ALKS showcases decent financial health and profitability, coupled with an attractive price. 
Via Chartmill
What 5 Analyst Ratings Have To Say About Alkermes
Via Benzinga
NASDAQ:ALKS, an undervalued stock with good fundamentals.
ALKERMES PLC (NASDAQ:ALKS): good value for what you're paying. 
Via Chartmill
NASDAQ:ALKS: good value for what you're paying.
Investors should take notice ofALKERMES PLC (NASDAQ:ALKS)—it offers a great deal for the fundamentals it presents. 
Via Chartmill
A Glimpse Into The Expert Outlook On Alkermes Through 9 Analysts
Via Benzinga
Stocks Trim Losses After Hot Inflation, Bonds Remain Pressured, Tesla Rebounds: What's Driving Markets Wednesday?
A hotter-than-expected inflation report initially rattled markets on Wednesday morning, but investors found confidence to buy the dip, helping major indexes recover most losses by midday trading in New... 
Via Benzinga
Topics Economy
Alkermes Plc EPS Soars Past Forecasts
Alkermes reported strong earnings by exceeding both revenue and earnings expectations in its latest quarterly release. 
Via The Motley Fool
NASDAQ:ALKS is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
When you look at ALKERMES PLC (NASDAQ:ALKS), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. 
Via Chartmill
NASDAQ:ALKS is an undervalued gem with solid fundamentals.
ALKERMES PLC (NASDAQ:ALKS), an undervalued stock with good fundamentals. 
Via Chartmill
Alkermes's Earnings: A Preview
Via Benzinga
Decoding 7 Analyst Evaluations For Alkermes
Via Benzinga
Alkermes Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Charter Communications To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
Alkermes Stock Jumps Nearly 30% In 3 Months Amid Hefty Profits
Alkermes develops treatments for neurodegenerative diseases (conditions that damage and destroy parts of the nervous system) and cancer. 
Via Investor's Business Daily
Despite its impressive fundamentals, NASDAQ:ALKS remains undervalued.
ALKERMES PLC (NASDAQ:ALKS) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. 
Via Chartmill
NASDAQ:ALKS: good value for what you're paying.
For those who appreciate value investing, ALKERMES PLC (NASDAQ:ALKS) is a compelling option with its solid fundamentals. 
Via Chartmill
Despite its impressive fundamentals, NASDAQ:ALKS remains undervalued.
For those who appreciate value investing, ALKERMES PLC (NASDAQ:ALKS) is a compelling option with its solid fundamentals. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.